ACTRN12613000279729招募中3 期
TROG 12.01 A Randomised Trial of Weekly Cetuximab and Radiation versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma
Trans-Tasman Radiation Oncology Group0 个研究点目标入组 200 人开始时间: 2013年3月8日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Aged 18 years or older
- •2. Has provided written Informed Consent for participation in this trial
- •3. Histologically confirmed squamous cell carcinoma of the oropharynx with p16 positive status confirmed locally by immunohistochemistry
- •4. Stage III (excluding T1-2N1) or stage IV (excluding T4, N3, and distant metastasis) if smoking history of < /=10 pack years. If > 10 pack years nodal disease must be N0 – N2a.
- •5. If an excisional biopsy has been performed, patients remain eligible for the study provided there is clinically measurable disease prior to commencing RT. The residual disease should still meet the stage criteria required for the trial e.g. excisional biopsy of a node with residual T3 primary, or tonsillectomy for T1 primary with residual > N2a nodes.
- •6. No prior treatment for oropharyngeal cancer
- •7. Adequate haematological, renal, and hepatic function as defined by,
- •a) Absolute neutrophil count (ANC, segs + bands) > /= 1.5 x 109/L
- •b) Platelet count > /= 100 x 109/L
- •c) Total bilirubin < /= 1.5 x upper normal limit
- •d) ALT < /= 2.5 x upper normal limit
- •e) Calculated creatinine clearance (Cockcroft-Gault formula) or isotopic GFR > 55ml/min
- •8. ECOG performance status score of 0-1
- •9. Participants capable of childbearing are using adequate contraception and intend to continue use of contraception for at least 6 months following completion of treatment
- •10. Negative pregnancy test within 72 hours prior to randomisation of women who are of childbearing potential
- •11. Suitable for follow-up for at least 24 months as per trial protocol.
- •12. Sufficient proficiency in English, cognitive capacity and willingness to complete questionnaires
排除标准
- •1. History of unknown primary of the head and neck
- •2. T4, N3 or distant metastases
- •3. Smoking history >10 pack years with N2b or c nodal status
- •4. Women who are pregnant or lactating.
- •5. Previous radiotherapy to the area to be treated (excluding superficial radiotherapy for a cutaneous malignancy)
- •6. Previous cisplatin or carboplatin chemotherapy
- •7. Prior EGFR targeted therapy of any kind
- •8. Primary surgery to the affected area (excisional biopsy allowed)
- •9. Peripheral neuropathy > /= grade 2 (CTCAE v4.0)
- •10. Sensori-neural hearing impairment >= grade 2 (CTCAE v4.0, hearing impaired, not enrolled on a monitoring program) which may be exacerbated by cisplatin (Audiometric abnormalities without corresponding clinical deafness will not be grounds for exclusion)
- •11. Tinnitus > /= grade 2 (CTCAE v4.0)
- •12. History of interstitial lung disease or evidence of interstitial lung disease on pre-registration CT
- •13. History of myocardial infarction within 12 months prior to study entry, uncontrolled congestive heart failure, unstable angina, active cardiomyopathy, unstable arrhythmia, uncontrolled psychotic disorders, active serious infections, active peptic ulcer disease, immunosuppression due to post-organ transplantation or use of immunosuppressants for autoimmune disorders
- •14. Patients known to be HIV positive
- •15. Other cancer that was diagnosed:
- •a) more than 5 years prior to current diagnosis with (i) subsequent evidence of disease recurrence or (ii) clinical expectation of recurrence is greater than 10% or
- •b) within 5 years of the current diagnosis, with the exception of successfully treated basal cell or squamous cell skin carcinoma, in situ melanoma, or carcinoma in situ of the cervix
研究者
相似试验
已完成
2 期
Randomized phase II study of biweekly cetuximab versus panitumumab in patients not combination of irinotecan wild-type KRAS metastatic colorectal cancer following treatment with fluoropyrimidine and oxaliplatin chemotherapyadvanced colorectal cancerJPRN-UMIN000006899Tsukuba Center Clinical Trial Group(TCTG)90
进行中（未招募）
1 期
Randomised study of the efficacy of cetuximab rechallenge in patients with metastatic colorectal cancer (RAS wild-type) responding to first-line treatment with FOLFIRI plus cetuximabHistologically confirmed, UICC stage IV adenocarcinoma of the colon or rectum (metastatic colorectal cancer), primarily non-resectable or with surgery refused by the patientMedDRA version: 27.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003787-21-ATKlinikum der Ludwig-Maximilians-Univ. Münch , Klinikum Großhadern (vertreten durch die kaufmännische Direktion)700
进行中（未招募）
1 期
Randomised study of the efficacy of cetuximab rechallenge in patients with metastatic colorectal cancer (RAS wild-type) responding to first-line treatment with FOLFIRI plus cetuximabHistologically confirmed, UICC stage IV adenocarcinoma of the colon or rectum (metastatic colorectal cancer), primarily non-resectable or with surgery refused by the patientMedDRA version: 27.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003787-21-DEKlinikum der Ludwig-Maximilians-Univ. Münch , Klinikum Großhadern (vertreten durch die kaufmännische Direktion)700
已完成
2 期
Chemoradiation Treatment for Head and Neck Cancerocally Advanced Head and Neck Squamous Cell CarcinomaLocally Advanced Head and Neck Squamous Cell CarcinomaCancer - Head and neckACTRN12613000695707Trans Tasman Radiation Oncology Group60
已完成
2 期
Phase II study of biweekly cetuximab therapy for unresectable colorectal cancerunresectable colorectal cancerJPRN-UMIN000011361Department of Surgical Oncology Osaka City University10